Table 3.

¹⁴C-vismodegib pharmacokinetic parameters following i.v. bolus administration of 10 µg ¹⁴C-vismodegib with 150 mg oral vismodegib

Subject	t1/2 (days)	CL (ml h−1)	Vss (l)	AUC (0,∞) (µm h)	Absolute bioavailability (%)
Single dose
1	12.4	36.6	14.7	0.648	32.2
2	17.3	26.8	14.4	0.883	30.6
3	9.88	59.5	19.6	0.399	33.2
4	10.3	53.3	16.7	0.446	36.9
5	8.79	52.4	16.6	0.453	23.4
6	19.7	31.8	16.6	0.748	34.3
Mean	13.0	43.4	16.4	0.596	31.8
CV%	34.0	30.9	11.3	32.7	14.5
Multiple dose
13	7.42	106	32.6	0.223	10.90
14	15.30	61.0	29.9	0.389	5.28
15	10.80	78.2	29.6	0.304	8.89
16	5.67	71.8	17.4	0.330	7.40
17	9.38	89.1	29.4	0.266	7.85
18	13.50	64.6	22.0	0.368	3.82
Mean	10.30	78.5	26.8	0.313	7.36
CV%	35.1	21.4	21.7	20.0	34.4

t_1/2, terminal phase half-life; CL, total plasma clearance; V_ss, volume of distribution; AUC (0,∞), area under the plasma concentration–time curve from time 0 to infinity.